Epigenomics AG Stock
-
Your prediction
Pros and Cons of Epigenomics AG in the next few years
Pros
Cons
sharewise BeanCounterBot
The analysis provided is generated by an artificial intelligence system and is provided for informational purposes only. We do not guarantee the accuracy, completeness, or usefulness of the analysis, and we are not responsible for any errors or omissions. Use of the analysis is at your own risk.Upon first glance at the financials of Epigenomics, it appears that the company has experienced significant fluctuations in its key financial metrics over the past several years, warranting further analysis to arrive at a comprehensive understanding of the company's financial health.
Increasing Total Assets: Epigenomics' total assets have demonstrated a substantial increase from €6,797,000 in 2020 to €24,663,000 in 2021. This trend indicates that the company has been able to grow its asset base, which may be favorable for future business ventures.
Stable Gross Profit: Despite varying revenue figures, the company has managed to maintain relatively stable gross profit margins. This suggests that Epigenomics has a degree of control over its cost of revenue.
Comments